Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eribulin mesylate - Eisai Co Ltd

Next Previous
Drug Profile

Eribulin mesylate - Eisai Co Ltd

Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Halaven; Halichondrin B Analog; NSC-707389; TECERIS

Latest Information Update: 08 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd; Harvard University; Japan Agency for Medical Research and Development
  • Developer Academic and Community Cancer Research United; Asan Medical Center; Big Ten Cancer Research Consortium; Eisai Co Ltd; Emory University; Icahn School of Medicine at Mount Sinai; Medica Scientia Innovation Research; Merck & Co; National Cancer Center Hospital East; National Cancer Institute (USA); Pfizer; PRISM Pharma Co
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Transcription factor modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Soft tissue sarcoma
  • Phase III Non-small cell lung cancer
  • Phase II Ewing's sarcoma; Glioblastoma; Haemangiosarcoma
  • Phase I/II Colorectal cancer; Liver cancer; Malignant melanoma; Solid tumours
  • No development reported Ovarian cancer; Urogenital cancer
  • Discontinued Bladder cancer; Prostate cancer

Most Recent Events

  • 17 Apr 2026 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 17 Oct 2025 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 30 May 2025 Efficacy and adverse events data from a phase Ib trial in Liver cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top